📊TATA ELXSI LIMITED (#TATAELXSI)

🏷Market Cap: 52,550 Cr

🏷One of the World’s leading provider of design and technology services across industries including Automotive, Broadcast & communications and Healthcare

💥Business Analysis

A Thread 🧵

🌁BUSINESS

🏷Part of prestigious TATA Group

🏷Established in 1989, A forward looking IT business

🏷Company earns revenue primarily from providing information technology, engineering design, systems integration & support services, sale of licenses and maintenance of equipment
🌁The company operates in 2 segments

1. Software Development & Services

It is further sub divided into EPD and IDV.

🏷Embedded Product Design (EPD)
🏷Industrial Design & Visualisation (IDV) division

2. System Integration & Support (SIS)
🌁MANAGEMENT

🏷Manoj Raghavan (MD & CEO) : 22 Years of experience (2.42 Yrs tenure)

🏷CEO compensation ($USD 578.96K) is below average for companies of similar size

🏷CEO compensation has increased by more than 20% in the past year
🌁SHAREHOLDING PATTERN

🏷Change in promoter holding (Vs last quarter): -0.21%

🏷Change in FII holding (Vs last quarter): -0.78%

🏷Change in DII holding (Vs last quarter): +0.59%

🏷Change in public holding (Vs last quarter): +0.41%
🌁CONTRIBUTION TO DIFFERENT INDUSTRIES

Company is mainly working for below industries

1. Automotive
2. Broadcast & Communications
3. Healthcare
🌁WELL DIVERSIFIED REVENUE MIX (Q3 FY22)

🏷Geography

Americas: 42.3%, Europe: 32.8%, India: 16.7%, RoW: 8.2%

🏷Segment

Embedded Product Design: 88.9%
Industrial Design & Visualisation: 8.9%
System Integration & Support: 2.2%
🌁Client concentration & Employee Metrics

🏷People addition in Q3 FY22: 414

🏷Employee utilisation rate ~83%

❌Attrition Rate: 18.2% (LTM)
🌁QUARTERLY RESULTS (Q3 FY22)

🏷Sales Growth: 33.2% YoY - Good YoY Sales Growth

🏷Profit: 43.5% YoY - Good YoY Profit Growth

🏷Consistent growth in margins

🏷Strong order book and a healthy deal pipeline

🏷The company is debt free since long
🌁FINANCIALS (5 Year CAGR)

🏷Sales Growth: 11.2%

🏷EBITDA Growth: 16.2%

🏷PAT Growth: 18.9%

🏷ROCE: 42.5% (FY21)

🏷ROE: 30.2%

Working capital days of the company in FY21 stood at ~65 days

Free cash flow per share increased to 62 Rs in FY 21

Overall, Numbers look good.
🌁STRENGTHS

🏷Diversified geographical presence
🏷Established market position
🏷Healthy financial operations
🏷Major contributor to the transformation to Electric Vehicle
🏷Company consistently making profits
🏷Debt free since long
🏷Brokers upgraded recommendation
🌁WEAKNESS

🏷Trading at Premium Valuation
🏷Promoter and FII reduced the holding in Q3 FY22
🏷Good competition from KPIT and LTTS
🏷~88% revenue from one segment, Embedded Product Design
🌁VALUATION

🏷Price to Earnings (PE): 104 (Above it’s median PE 27.6)
🏷Price to book value: 40.7
🏷PEG Ratio: 5.53

Although there is bright growth prospect, at current levels stock is trading at premium valuation (Overvalued).
🌁CHART (Weekly Timeframe)

More from Tataelxsi

You May Also Like

@franciscodeasis https://t.co/OuQaBRFPu7
Unfortunately the "This work includes the identification of viral sequences in bat samples, and has resulted in the isolation of three bat SARS-related coronaviruses that are now used as reagents to test therapeutics and vaccines." were BEFORE the


chimeric infectious clone grants were there.https://t.co/DAArwFkz6v is in 2017, Rs4231.
https://t.co/UgXygDjYbW is in 2016, RsSHC014 and RsWIV16.
https://t.co/krO69CsJ94 is in 2013, RsWIV1. notice that this is before the beginning of the project

starting in 2016. Also remember that they told about only 3 isolates/live viruses. RsSHC014 is a live infectious clone that is just as alive as those other "Isolates".

P.D. somehow is able to use funds that he have yet recieved yet, and send results and sequences from late 2019 back in time into 2015,2013 and 2016!

https://t.co/4wC7k1Lh54 Ref 3: Why ALL your pangolin samples were PCR negative? to avoid deep sequencing and accidentally reveal Paguma Larvata and Oryctolagus Cuniculus?